Beta Bionics CPO Mike Mensinger sells $58,300 in stock

Mike Mensinger, the Chief Product Officer at Beta Bionics, Inc., sold 2,650 shares of the company's common stock on October 27, 2026. The sale was conducted at a price of $22.00 per share, amounting to $58,300 in total. The transaction followed a pre-established Rule 10b5-1 trading plan, which Mr. Mensinger had established on September 8, 2025.

After this sale, Mr. Mensinger continues to own 174,740 shares of Beta Bionics common stock. Recently, Beta Bionics announced a substantial increase in third-quarter revenue, reaching a record $35.5 million, a 30% increase from the previous year. However, the company reported a larger-than-expected loss, resulting in an adjusted earnings per share (EPS) of -$0.52, which fell short of the consensus estimate of -$0.32.

In response, Beta Bionics adjusted its full-year 2026 revenue guidance upward to a range of $124 million to $126 million. Truist Securities maintained a Buy rating on the stock, setting a price target of $28.00, commending the company's robust revenue growth while acknowledging difficulties with gross margins due to the dynamics of durable medical equipment stocking.

On the other hand, TD Cowen raised its price target for Beta Bionics to $21.00 from $18.00, retaining a Hold rating. The firm noted that third-quarter pump shipments were slightly lower than anticipated, but pointed out that revenue performance outpaced shipment numbers. The Mint patch pump from Beta Bionics is anticipated for commercialization in the United States starting in the first quarter of 2027.

This report was produced with AI assistance and reviewed by a human editor. For additional details, please refer to the source's Terms and Conditions.